XPO1 and plasma cell myeloma: Eltanexor (KPT-8602) is a novel second-generation XPO1 inhibitor currently under investigation in preclinical and early clinical settings for several cancer entities (colorectal, multiple myeloma, myelodysplastic syndrome, ALL subtypes, etc.)[51,52,53,54].